Masimo Corp
NASDAQ:MASI
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
92.89
172.96
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MASI stock under the Base Case scenario is 128.09 USD. Compared to the current market price of 172.96 USD, Masimo Corp is Overvalued by 26%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Masimo Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MASI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Masimo Corp. is a pioneering medical technology company that specializes in innovative non-invasive monitoring solutions. Founded in 1989 and headquartered in Irvine, California, Masimo revolutionized the field of patient monitoring with its groundbreaking pulse oximetry technology, which provides accurate blood oxygen saturation levels in a wide range of settings, from hospitals to home care. The company has continued to expand its product portfolio, introducing advanced monitoring solutions that measure multiple physiological parameters critical for patient care. With a strong emphasis on research and development, Masimo maintains a competitive edge, driving both innovation and customer lo...
Masimo Corp. is a pioneering medical technology company that specializes in innovative non-invasive monitoring solutions. Founded in 1989 and headquartered in Irvine, California, Masimo revolutionized the field of patient monitoring with its groundbreaking pulse oximetry technology, which provides accurate blood oxygen saturation levels in a wide range of settings, from hospitals to home care. The company has continued to expand its product portfolio, introducing advanced monitoring solutions that measure multiple physiological parameters critical for patient care. With a strong emphasis on research and development, Masimo maintains a competitive edge, driving both innovation and customer loyalty across the global healthcare market.
For investors, Masimo presents a compelling growth story. As the demand for effective remote patient monitoring rises, driven by trends in telehealth and an aging population, the company is well-positioned to capitalize on these opportunities. Masimo's focus on integrating sophisticated technologies, such as measure-through motion and low perfusion capabilities, sets it apart from traditional monitoring devices. Moreover, with a solid financial foundation and a history of steady revenue growth, Masimo continues to demonstrate resilience in the face of market challenges. This combination of innovation, market demand, and financial stability makes Masimo Corp. an intriguing option for investors looking to tap into the evolving landscape of healthcare technology.
Masimo Corporation is a global medical technology company known for its innovative non-invasive monitoring technologies. The core business segments of Masimo typically include:
-
Non-Invasive Monitoring: This segment focuses on the development and sale of non-invasive monitoring devices that measure various physiological parameters. The flagship product in this category is the Pulse CO-Oximetry technology, which provides critical insights such as blood oxygen saturation, pulse, respiratory rate, and other key vitals without the need for invasive procedures.
-
Hospital Products: Masimo offers a range of products designed for hospital and clinical settings, including patient monitoring systems and software platforms. These products are used in various departments, such as anesthesia, surgery, and critical care, ensuring patient safety and improving clinical outcomes.
-
Home Care: This segment encompasses technologies and devices designed for outpatient and home healthcare monitoring. With a growing trend towards telehealth and home monitoring, Masimo has developed solutions that allow continuous monitoring of patients' vital signs in a non-hospital environment.
-
Consumer Products: Masimo has also expanded its offerings to include consumer health devices, leveraging its technology to cater to the growing consumer market for health monitoring. This includes products that can be used by individuals for self-assessment of their health.
-
Research and Development (R&D): While not a direct product segment, R&D plays a critical role in Masimo’s business strategy. Constant innovation in technologies, such as the development of advanced algorithms and new monitoring capabilities, supports all other segments and helps maintain a competitive edge.
-
Services and Software Solutions: This includes software development and integration services that enhance the functionality of devices and provide data management solutions for healthcare providers. It also covers training and support services to help medical staff effectively use Masimo’s products.
Overall, Masimo's core segments revolve around its commitment to developing innovative, non-invasive monitoring technologies that improve patient outcomes and enhance healthcare delivery. The company continues to focus on expanding its product offerings and entering new markets to drive growth.
Masimo Corp, known for its innovative noninvasive monitoring technologies, holds several unique competitive advantages over its rivals:
-
Innovative Product Portfolio: Masimo's flagship product, pulse oximetry, utilizes advanced signal extraction technology (SET) to enhance accuracy under challenging conditions, such as low perfusion and motion. This has made it a preferred choice in critical care environments.
-
Strong Intellectual Property: The company has a robust portfolio of patents that protect its proprietary technologies and innovations, providing a barrier to entry for competitors.
-
Regulatory Approvals: Masimo has successfully navigated complex regulatory environments to obtain FDA and CE mark approvals for its devices, establishing credibility and trust in its products.
-
Diverse Applications: Beyond pulse oximetry, Masimo has expanded its applications into areas like noninvasive blood monitoring and diagnostics, allowing it to serve a broader range of healthcare needs and markets.
-
Strategic Partnerships: Collaborations with major hospitals, healthcare organizations, and medical device manufacturers enhance Masimo's market presence and distribution capabilities, giving it access to a wider customer base.
-
Focus on Research and Development: Masimo invests significantly in R&D to continuously innovate and improve its technologies, staying at the forefront of noninvasive monitoring solutions, which can lead to better patient outcomes.
-
Strong Brand Reputation: The company is regarded as a leader in the field of noninvasive monitoring, with a reputation for high-quality products and reliable performance, which fosters customer loyalty and retention.
-
Global Reach: Masimo has established a presence in multiple international markets, diversifying its revenue streams and reducing dependence on any single region.
-
High Switching Costs: Once healthcare providers adopt Masimo's technologies, the integration into their systems creates high switching costs, making it less likely for them to switch to competitors.
These competitive advantages help Masimo maintain a strong position in the healthcare monitoring market, enabling it to not only compete effectively but also to drive innovation and growth.
Masimo Corp, a leader in non-invasive monitoring technologies, faces several risks and challenges in the near future:
-
Regulatory Risks: As a medical device company, Masimo is subject to stringent regulatory requirements by bodies like the FDA. Changes in regulations or delays in approval for new products can impact growth and market entry.
-
Market Competition: The healthcare technology market is highly competitive, with numerous players (including new entrants and established firms). Competitors can introduce similar or superior products, which may erode Masimo's market share.
-
Technological Change: Rapid advancements in technology require continuous investment in research and development. Failure to innovate or keep pace with new technologies could hinder Masimo's competitive advantage.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by events such as the COVID-19 pandemic, can affect production and delivery of products. Any disruptions might impact sales and customer satisfaction.
-
Economic Conditions: Economic downturns can lead to reduced healthcare spending, affecting demand for Masimo's products. Hospitals may delay purchases or reduce budgets for monitoring technologies during tough economic times.
-
Litigation Risks: As in any industry, Masimo may be exposed to lawsuits related to product liability, patents, or other issues. Legal challenges can be costly and can divert resources and management attention.
-
Reimbursement Challenges: Changes in reimbursement policies from insurance companies or government programs can affect the profitability of Masimo’s products. If products are not adequately reimbursed, hospitals may be less likely to adopt them.
-
International Market Risks: Expanding into international markets presents challenges, such as differing regulatory environments, cultural differences, and foreign exchange fluctuations, which could impact financial performance.
-
Dependence on Key Customers: Reliance on a limited number of significant customers, such as hospitals or healthcare systems, can pose a risk if those customers decide to switch suppliers or reduce spending.
-
Cybersecurity Threats: As Masimo's devices become more integrated with digital technologies, cybersecurity threats may pose significant risks, including data breaches that could compromise patient data and damage the company's reputation.
Addressing these risks proactively through strategic planning, innovation, and robust risk management practices will be essential for Masimo to maintain its market position and ensure long-term growth.
Revenue & Expenses Breakdown
Masimo Corp
Balance Sheet Decomposition
Masimo Corp
Current Assets | 1.3B |
Cash & Short-Term Investments | 158.5m |
Receivables | 444.6m |
Other Current Assets | 676.8m |
Non-Current Assets | 1.8B |
Long-Term Investments | 9.4m |
PP&E | 501m |
Intangibles | 1.1B |
Other Non-Current Assets | 244.2m |
Current Liabilities | 637.6m |
Accounts Payable | 280.8m |
Accrued Liabilities | 203.5m |
Other Current Liabilities | 153.3m |
Non-Current Liabilities | 987m |
Long-Term Debt | 733.2m |
Other Non-Current Liabilities | 253.8m |
Earnings Waterfall
Masimo Corp
Revenue
|
2B
USD
|
Cost of Revenue
|
-1B
USD
|
Gross Profit
|
1B
USD
|
Operating Expenses
|
-861.3m
USD
|
Operating Income
|
161.1m
USD
|
Other Expenses
|
-82.5m
USD
|
Net Income
|
78.6m
USD
|
Free Cash Flow Analysis
Masimo Corp
USD | |
Free Cash Flow | USD |
In the third quarter, Masimo reported healthcare revenue of $343 million, achieving 12% year-over-year growth, while non-healthcare revenue decreased by 6%. The company improved its consolidated non-GAAP gross margin to 54%, driven by operational efficiencies and manufacturing shifts to Malaysia, resulting in expected margins of 63% in Q4. For 2024, Masimo projects consolidated revenue between $2.75 billion and $2.85 billion, with healthcare growth between 9% to 10%. They aim for an EPS of $3.95 to $4.10, reflecting efficient expense management. The company's focus remains on long-term growth initiatives while managing its consumer business strategic review.
What is Earnings Call?
MASI Profitability Score
Profitability Due Diligence
Masimo Corp's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Masimo Corp's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
MASI Solvency Score
Solvency Due Diligence
Masimo Corp's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Masimo Corp's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MASI Price Targets Summary
Masimo Corp
According to Wall Street analysts, the average 1-year price target for MASI is 172.51 USD with a low forecast of 146.45 USD and a high forecast of 199.5 USD.
Dividends
Current shareholder yield for MASI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MASI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. The company is headquartered in Irvine, California and currently employs 2,200 full-time employees. The company went IPO on 2007-08-08. The firm's patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners. The company has developed Masimo Signal Extraction Technology (SET), which provides the capabilities of Measure-through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. The firm's technology offerings also include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet and Masimo Patient SafetyNet Surveillance.
Officers
The intrinsic value of one MASI stock under the Base Case scenario is 128.09 USD.
Compared to the current market price of 172.96 USD, Masimo Corp is Overvalued by 26%.